The ongoing pursuit of neuroprotective therapies in Parkinson disease (original) (raw)

• Duncan, G. W. et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov. Disord. 29, 195–202 (2014).
  Article PubMed Google Scholar
• Lawson, R. A. et al. Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism Relat. Disord. 20, 1071–1075 (2014).
  Article PubMed PubMed Central Google Scholar
• Hirsch, E. C., Jenner, P. & Przedborski, S. Pathogenesis of Parkinson's disease. Mov. Disord. 28, 24–30 (2013).
  Article CAS PubMed Google Scholar
• Schapira, A. H. V. & Tolosa, E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6, 309–317 (2010).
  Article CAS PubMed Google Scholar
• Foltynie, T. & Kahan, J. Parkinson's disease: an update on pathogenesis and treatment. J. Neurol. 260, 1433–1440 (2013).
  Article CAS PubMed Google Scholar
• Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T. & Bezard, E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384, 545–555 (2014).
  Article CAS PubMed Google Scholar
• Olanow, C. W. & Kordower, J. H. Modeling Parkinson's disease. Ann. Neurol. 66, 432–436 (2009).
  Article CAS PubMed Google Scholar
• Blandini, F. & Armentero, M.-T. Animal models of Parkinson's disease. FEBS J. 279, 1156–1166 (2012).
  Article CAS PubMed Google Scholar
• Bezard, E., Yue, Z., Kirik, D. & Spillantini, M. G. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov. Disord. 28, 61–70 (2013).
  Article CAS PubMed Google Scholar
• Pifl, C., Schingnitz, G. & Hornykiewicz, O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44, 591–605 (1991).
  Article CAS PubMed Google Scholar
• Mounayar, S. et al. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130, 2898–2914 (2007).
  Article PubMed Google Scholar
• Iravani, M. M. et al. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur. J. Neurosci. 21, 841–854 (2005).
  Article PubMed Google Scholar
• Duty, S. & Jenner, P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 164, 1357–1391 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ekstrand, M. I. & Galter, D. The MitoPark Mouse—an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat. Disord. 15 (Suppl. 3), S185–S188 (2009).
  Article PubMed Google Scholar
• Volpicelli-Daley, L. A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Luk, K. C. & Lee, V. M. Modeling Lewy pathology propagation in Parkinson's disease. Parkinsonism Relat. Disord. 20 (Suppl. 1), S85–S87 (2014).
  Article PubMed PubMed Central Google Scholar
• Fahn, S. et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498–2508 (2004).
  Article CAS PubMed Google Scholar
• Lang, A. E., Melamed, E., Poewe, W. & Rascol, O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov. Disord. 28, 86–95 (2013).
  Article CAS PubMed Google Scholar
• D'Agostino, R. B. Sr. The delayed-start study design. N. Engl. J. Med. 361, 1304–1306 (2009).
  Article CAS PubMed Google Scholar
• Elm, J. J. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1. Mov. Disord. 27, 1513–1521 (2012).
  Article CAS PubMed Google Scholar
• Fearnley, J. M. & Lees, A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283–2301 (1991).
  Article PubMed Google Scholar
• Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136, 2419–2431 (2013).
  Article PubMed PubMed Central Google Scholar
• Schwingenschuh, P. et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov. Disord. 25, 560–569 (2010).
  Article PubMed PubMed Central Google Scholar
• Foltynie, T., Brayne, C. & Barker, R. A. The heterogeneity of idiopathic Parkinson's disease. J. Neurol. 249, 138–145 (2002).
  Article PubMed Google Scholar
• Dragalin, V. An introduction to adaptive designs and adaptation in CNS trials. Eur. Neuropsychopharmacol. 21, 153–158 (2011).
  Article CAS PubMed Google Scholar
• Kang, J.-H. et al. Association of cerebrospinal fluid β-amyloid 1–42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70, 1277–1287 (2013).
  PubMed PubMed Central Google Scholar
• Agarwal, P. A. & Stoessl, A. J. Biomarkers for trials of neuroprotection in Parkinson's disease. Mov. Disord. 28, 71–85 (2013).
  Article CAS PubMed Google Scholar
• Olanow, C. W. et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 5, 1013–1020 (2006).
  Article CAS PubMed Google Scholar
• Ward, C. D. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J. Neurol. Neurosurg. Psychiatry 57, 217–220 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Sherer, T. B., Chowdhury, S., Peabody, K. & Brooks, D. W. Overcoming obstacles in Parkinson's disease. Mov. Disord. 27, 1606–1611 (2012).
  Article PubMed Google Scholar
• Tardiff, D. F. et al. Yeast reveal a “druggable” Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science 342, 979–983 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Chung, C. Y. et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342, 983–987 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Mortiboys, H., Aasly, J. & Bandmann, O. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 136, 3038–3050 (2013).
  Article PubMed Google Scholar
• Chan, C. S., Gertler, T. S. & Surmeier, D. J. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov. Disord. 25 (Suppl. 1), S63–S70 (2010).
  Article PubMed Google Scholar
• Hurley, M. J., Brandon, B., Gentleman, S. M. & Dexter, D. T. Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136, 2077–2097 (2013).
  Article PubMed Google Scholar
• Becker, C., Jick, S. S. & Meier, C. R. Use of antihypertensives and the risk of Parkinson disease. Neurology 70, 1438–1444 (2008).
  Article CAS PubMed Google Scholar
• Ritz, B. et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600–606 (2010).
  CAS PubMed PubMed Central Google Scholar
• Pasternak, B. et al. Use of calcium channel blockers and Parkinson's disease. Am. J. Epidemiol. 175, 627–635 (2012).
  Article PubMed Google Scholar
• Marras, C. et al. Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann. Neurol. 71, 362–369 (2012).
  Article CAS PubMed Google Scholar
• Ilijic, E., Guzman, J. N. & Surmeier, D. J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 43, 364–371 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, C. S. et al. “Rejuvenation” protects neurons in mouse models of Parkinson's disease. Nature 447, 1081–1086 (2007).
  Article CAS PubMed Google Scholar
• Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov. Disord. 28, 1823–1831 (2013).
• Kang, S. et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat. Commun. 3, 1146 (2012).
  Article PubMed CAS Google Scholar
• Okada, M. et al. Exocytosis mechanism as a new targeting site for mechanisms of action of antiepileptic drugs. Life Sci. 72, 465–473 (2002).
  Article CAS PubMed Google Scholar
• Mochio, S. et al. Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease. Parkinsonism Relat. Disord. 18, 906–908 (2012).
  Article PubMed Google Scholar
• Asanuma, M. et al. Neuroprotective effects of zonisamide target astrocyte. Ann. Neurol. 67, 239–249 (2010).
  Article CAS PubMed Google Scholar
• Alam, Z. I. et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196–1203 (1997).
  Article CAS PubMed Google Scholar
• Pålhagen, S. et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66, 1200–1206 (2006).
  Article PubMed Google Scholar
• Olanow, C. W. et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268–1278 (2009).
  Article CAS PubMed Google Scholar
• Weisskopf, M. G., O'Reilly, E., Chen, H., Schwarzschild, M. A. & Ascherio, A. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166, 561–567 (2007).
  Article CAS PubMed Google Scholar
• Alonso, A., Rodríguez, L. A. G., Logroscino, G. & Hernán, M. A. Gout and risk of Parkinson disease: a prospective study. Neurology 69, 1696–1700 (2007).
  Article PubMed Google Scholar
• Shen, C., Guo, Y., Luo, W., Lin, C. & Ding, M. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can. J. Neurol. Sci. 40, 73–79 (2013).
  Article PubMed Google Scholar
• Schwarzschild, M. A. et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 65, 716–723 (2008).
  Article PubMed PubMed Central Google Scholar
• Ascherio, A. et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66, 1460–1468 (2009).
  Article PubMed PubMed Central Google Scholar
• Andreadou, E. et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg. 111, 724–728 (2009).
  Article PubMed Google Scholar
• Yamamoto, T. et al. Effect of inosine on the plasma concentration of uridine and purine bases. Metabolism 51, 438–442 (2002).
  Article CAS PubMed Google Scholar
• Schwarzschild, M. A. et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 71, 141–150 (2014).
  Article PubMed Google Scholar
• Grayson, P. C., Kim, S. Y., LaValley, M. & Choi, H. K. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 63, 102–110 (2011).
  Article CAS Google Scholar
• Takanashi, M. et al. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). Parkinsonism Relat. Disord. 7, 311–314 (2001).
  Article CAS PubMed Google Scholar
• Sian-Hülsmann, J., Mandel, S., Youdim, M. B. & Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem. 118, 939–957 (2011).
  Article PubMed CAS Google Scholar
• Crichton, R. & Ward, R. in Metal-Based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies 2nd edn Vol. 1 Ch. 6 148–153 (John Wiley & Sons, 2014).
  Google Scholar
• Jamuar, S. S. & Lai, A. H. Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther. Adv. Hematol. 3, 299–307 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Molina-Holgado, F., Gaeta, A., Francis, P. T., Williams, R. J. & Hider, R. C. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J. Neurochem. 105, 2466–2476 (2008).
  Article CAS PubMed Google Scholar
• Dexter, D. T. et al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J. Neural Transm. 118, 223–231 (2011).
  Article CAS PubMed Google Scholar
• Devos, D. et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. 21, 195–210 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Hauser, R. A., Lyons, K. E., McClain, T., Carter, S. & Perlmutter, D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov. Disord. 24, 979–983 (2009).
  Article PubMed Google Scholar
• Chinta, S. J. & Andersen, J. K. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic. Biol. Med. 41, 1442–1448 (2006).
  Article CAS PubMed Google Scholar
• Sian, J. et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348–355 (1994).
  Article CAS PubMed Google Scholar
• Riederer, P. et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515–520 (1989).
  Article CAS PubMed Google Scholar
• Dexter, D. T. et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35, 38–44 (1994).
  Article CAS PubMed Google Scholar
• Hauser, R. A., Lyons, K. E., McClain, T., Carter, S. & Perlmutter, D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov. Disord. 24, 979–983 (2009).
  Article PubMed Google Scholar
• Clark, J. et al. Oral _N_-acetyl-cysteine attenuates loss of dopaminergic terminals in α-synuclein overexpressing mice. PLoS ONE 5, e12333 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Katz, M., Swanson, R. A., Glass, G. A. Cerebrospinal fluid concentrations of _N_-acetylcysteine after oral administration: phase I trial in Parkinson's disease [abstract 664]. Mov. Disord. 29 (Suppl. 1), S247 (2014).
  Google Scholar
• Adair, J. C., Knoefel, J. E. & Morgan, N. Controlled trial of _N_-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57, 1515–1517 (2001).
  Article CAS PubMed Google Scholar
• Schapira, A. H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7, 97–109 (2008).
  Article CAS PubMed Google Scholar
• Tain, L. S. et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12, 1129–1135 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Carta, A. R. & Pisanu, A. Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotox. Res. 23, 112–123 (2013).
  Article CAS PubMed Google Scholar
• Khan, M. M. et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 1328, 139–151 (2010).
  Article CAS PubMed Google Scholar
• Lofrumento, D. D. et al. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun. 20, 249–260 (2014).
  Article PubMed CAS Google Scholar
• Rees, K. et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD008454. http://dx.doi.org/10.1002/14651858.CD008454.pub2.
• Bartels, A. L. et al. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat. Disord. 16, 57–59 (2010).
  Article CAS PubMed Google Scholar
• Imamura, K. et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 106, 518–526 (2003).
  Article CAS PubMed Google Scholar
• International Parkinson's Disease Genomics Consortium (IPDGC) & Wellcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet. 7, e1002142 (2011).
• Diani, A. R., Sawada, G., Wyse, B., Murray, F. T. & Khan, M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 286, E116–E122 (2004).
  Article CAS PubMed Google Scholar
• Heneka, M. T. et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice. Brain 128, 1442–1453 (2005).
  Article PubMed Google Scholar
• Okada, K., Yamashita, U. & Tsuji, S. Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice. Brain Res. 1102, 175–178 (2006).
  Article CAS PubMed Google Scholar
• Nakamura, T. et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 38, 3016–3022 (2007).
  Article CAS PubMed Google Scholar
• Schütz, B. et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25, 7805–7812 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Dehmer, T., Heneka, M. T., Sastre, M., Dichgans, J. & Schulz, J. B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκB alpha induction and block of NFκB and iNOS activation. J. Neurochem. 88, 494–501 (2004).
  Article CAS PubMed Google Scholar
• Breidert, T. et al. Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82, 615–624 (2002).
  Article CAS PubMed Google Scholar
• Swanson, C. R. et al. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J. Neuroinflammation 8, 91 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Suzuki, S. et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol. Sci. 113, 349–357 (2010).
  Article CAS PubMed Google Scholar
• Azoulay, L. et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344, e3645 (2012).
  Article PubMed PubMed Central Google Scholar
• Ferwana, M. et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet. Med. 30, 1026–1032 (2013).
  Article CAS PubMed Google Scholar
• Consoli, A. & Formoso, G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Obes. Metab. 15, 967–977 (2013).
  Article CAS PubMed Google Scholar
• Colca, J. R. et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)—relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE 8, e61551 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Colca, J. R. et al. Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 286, E252–E260 (2004).
  Article CAS PubMed Google Scholar
• Colca, J. R. et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin. Pharmacol. Ther. 93, 352–359 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Appel, S. H. Inflammation in Parkinson's disease: cause or consequence? Mov. Disord. 27, 1075–1077 (2012).
  Article CAS PubMed Google Scholar
• Choi, D.-K. et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 25, 6594–6600 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Posener, J. A., et al. Safety, tolerability, and pharmacodynamics of AZD3241, a myeloperoxidase inhibitor, in Parkinson's disease [abstract 698]. Mov. Disord. 29 (Suppl. 1), S259–S260 (2014).
  Google Scholar
• Selley, M. L. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 1037, 1–6 (2005).
  Article CAS PubMed Google Scholar
• Wang, Q., Wang, P. H., McLachlan, C. & Wong, P. T. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 1045, 229–233 (2005).
  Article CAS PubMed Google Scholar
• Hernández-Romero, M. C. et al. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J. Neurochem. 105, 445–459 (2008).
  Article PubMed CAS Google Scholar
• Santiago, M., Hernández-Romero, M. C., Machado, A. & Cano, J. Zocor Forte® (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not. Eur. J. Pharmacol. 609, 58–64 (2009).
  Article CAS PubMed Google Scholar
• Yan, J., Sun, J., Huang, L., Fu, Q. & Du, G. Simvastatin prevents neuroinflammation by inhibiting _N_-methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells. J. Neurosci. Res. 92, 634–640 (2014).
  Article CAS PubMed Google Scholar
• Bar-On, P. et al. Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson's disease. J. Neurochem. 105, 1656–1667 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, X., Simon, K. C., Schwarzschild, M. A. & Ascherio, A. Prospective study of statin use and risk of Parkinson disease. Arch. Neurol. 69, 380–384 (2012).
  Article PubMed PubMed Central Google Scholar
• Wahner, A. D., Bronstein, J. M., Bordelon, Y. M. & Ritz, B. Statin use and the risk of Parkinson disease. Neurology 70, 1418–1422 (2008).
  Article CAS PubMed Google Scholar
• Wolozin, B. et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 5, 20 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Becker, C., Jick, S. S. & Meier, C. R. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf. 31, 399–407 (2008).
  Article CAS PubMed Google Scholar
• Hippisley-Cox, J. & Coupland, C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340, c2197 (2010).
  Article PubMed PubMed Central Google Scholar
• Ritz, B. et al. Statin use and Parkinson's disease in Denmark. Mov. Disord. 25, 1210–1216 (2010).
  Article PubMed PubMed Central Google Scholar
• Huang, X. et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov. Disord. 22, 377–381 (2007).
  Article PubMed PubMed Central Google Scholar
• Lee, Y.-C. et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 81, 410–416 (2013).
  Article CAS PubMed Google Scholar
• Martin, F. L., Williamson, S. J., Paleologou, K. E., Allsop, D. & El-Agnaf, O. M. α-Synuclein and the pathogenesis of Parkinson's disease. Protein Pept. Lett. 11, 229–237 (2004).
  Article CAS PubMed Google Scholar
• Li, J.-Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503 (2008).
  Article CAS PubMed Google Scholar
• Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 13010–13015 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hansen, C. et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715–725 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mougenot, A.-L. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225–2228 (2012).
  Article CAS PubMed Google Scholar
• Tóth, G. et al. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS ONE 9, e87133 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Masliah, E. et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857–868 (2005).
  Article CAS PubMed Google Scholar
• Masliah, E. et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6, e19338 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Schneeberger, A, Mandler, M., Mattner, F. & Schmidt, W. Vaccination for Parkinson's disease. Parkinsonism Relat. Disord. 18 (Suppl. 1), S11–S13 (2012).
  Article PubMed Google Scholar
• Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–29752 (2006).
  Article CAS PubMed Google Scholar
• Lee, K.-W. et al. Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J. Neurosci. 31, 6963–6971 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Pérez-Revuelta, B. I. et al. Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis. 5, e1209 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Wahlqvist, M. L. et al. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat. Disord. 18, 753–758 (2012).
  Article PubMed Google Scholar
• Steele, J. W. et al. Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Mol. Psychiatry 18, 882–888 (2013).
  Article CAS PubMed Google Scholar
• Duran, R. et al. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov. Disord. 28, 232–236 (2013).
  Article CAS PubMed Google Scholar
• Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783–1794 (2009).
  Article PubMed PubMed Central Google Scholar
• Sardi, S. P. et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl Acad. Sci. USA 110, 3537–3542 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Zimran, A., Altarescu, G. & Elstein, D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis. 50, 134–137 (2013).
  Article CAS PubMed Google Scholar
• Bendikov-Bar, I., Maor, G., Filocamo, M. & Horowitz, M. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50, 141–145 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Olanow, C. W. & Schapira, A. H. Therapeutic prospects for Parkinson disease. Ann. Neurol. 74, 337–347 (2013).
  Article CAS PubMed Google Scholar
• Richter, F. et al. A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11, 840–856 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, G., Lu, Z.-H., Kulkarni, N., Amin, R. & Ledeen, R. W. Mice lacking major brain gangliosides develop parkinsonism. Neurochem. Res. 36, 1706–1714 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Schneider, J. S. et al. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 256, 843–846 (1992).
  Article CAS PubMed Google Scholar
• Schneider, J. S., Sendek, S., Daskalakis, C. & Cambi, F. GM1 ganglioside in Parkinson's disease: results of a five year open study. J. Neurol. Sci. 292, 45–51 (2010).
  Article CAS PubMed Google Scholar
• Schneider, J. S. et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J. Neurol. Sci. 324, 140–148 (2013).
  Article CAS PubMed Google Scholar
• Parkes, D. G., Mace, K. F. & Trautmann, M. E. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin. Drug Discov. 8, 219–244 (2013).
  Article CAS PubMed Google Scholar
• Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M. & Greig, N. H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 302, 881–888 (2002).
  Article CAS PubMed Google Scholar
• Perry, T. et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958–966 (2002).
  Article CAS PubMed Google Scholar
• Harkavyi, A. et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation 5, 19 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Kim, S., Moon, M. & Park, S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202, 431–439 (2009).
  Article CAS PubMed Google Scholar
• Bertilsson, G. et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86, 326–338 (2008).
  Article CAS PubMed Google Scholar
• Rampersaud, N. et al. Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. Neuropeptides 46, 183–193 (2012).
  Article CAS PubMed Google Scholar
• Chen, S., Liu, A., An, F., Yao, W. & Gao, X. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr.) 34, 1211–1224 (2012).
  Article CAS Google Scholar
• Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2364–2365 (2013).
  Article CAS Google Scholar
• Aviles-Olmos, I. et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337–444 (2014).
  Article CAS PubMed Google Scholar
• Ryan, G. J., Moniri, N. H. & Smiley, D. D. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 70, 1123–1131 (2013).
  Article CAS PubMed Google Scholar
• Chang, R. C., Ho, Y.-S., Wong, S., Gentleman, S. M. & Ng, H.-K. Neuropathology of cigarette smoking. Acta Neuropathol. 127, 53–69 (2014).
  Article CAS PubMed Google Scholar
• Tsuang, D. et al. Association between lifetime cigarette smoking and Lewy body accumulation. Brain Pathol. 20, 412–418 (2010).
  Article PubMed Google Scholar
• Hong, D.-P., Fink, A. L. & Uversky, V. N. Smoking and Parkinson's disease: does nicotine affect α-synuclein fibrillation? Biochim. Biophys. Acta 1794, 282–290 (2009).
  Article CAS PubMed Google Scholar
• Quik, M., Perez, X. A. & Bordia, T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov. Disord. 27, 947–957 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Shimohama, S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol. Pharm. Bull. 32, 332–336 (2009).
  Article CAS PubMed Google Scholar
• Ward, R. J., Lallemand, F., de Witte, P. & Dexter, D. T. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. Prog. Neurobiol. 85, 135–147 (2008).
  Article CAS PubMed Google Scholar
• Costa, G., Abin-Carriquiry, J. A. & Dajas, F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888, 336–342 (2001).
  Article CAS PubMed Google Scholar
• Ryan, R. E., Ross, S. A., Drago, J. & Loiacono, R. E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. 132, 1650–1656 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Parain, K., Marchand, V., Dumery, B. & Hirsch, E. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res. 890, 347–350 (2001).
  Article CAS PubMed Google Scholar
• Quik, M. et al. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci. 26, 4681–4689 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Brundin, P. et al. Linked clinical trials—the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J. Parkinsons Dis. 3, 231–239 (2013).
  PubMed PubMed Central Google Scholar
• Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837–844 (2008).
  Article PubMed Google Scholar
• Muslimovic, D., Post, B., Speelman, J. D. & Schmand, B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65, 1239–1245 (2005).
  Article PubMed Google Scholar
• Rolinski, M., Fox, C., Maidment, I. & McShane, R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD006504. http://dx.doi.org/10.1002/14651858.CD006504.pub2.
• Broadstock, M., Ballard, C. & Corbett, A. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin. Pharmacother. 15, 1797–1810 (2014).
  Article CAS PubMed Google Scholar
• Irwin, D. J. et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587–598 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Masliah, E. et al. β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 12245–12250 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Jellinger, K. A., Seppi, K., Wenning, G. K. & Poewe, W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J. Neural Transm. 109, 329–339 (2002).
  Article CAS PubMed Google Scholar
• Kotzbauer, P. T. et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch. Neurol. 69, 1326–1331 (2012).
  Article PubMed PubMed Central Google Scholar
• Compta, Y. et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134, 1493–1505 (2011).
  Article PubMed Google Scholar
• Irwin, D. J., Lee, V. M. & Trojanowski, J. Q. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci. 14, 626–636 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Simón-Sánchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308–1312 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Morley, J. F. et al. Genetic influences on cognitive decline in Parkinson's disease. Mov. Disord. 27, 512–518 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Edwards, T. L. et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74, 97–109 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Goris, A. et al. Tau and α-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann. Neurol. 62, 145–153 (2007).
  Article CAS PubMed Google Scholar
• Tariot, P. N. et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry 68, 853–861 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, X. et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer's disease transgenic mouse model. J. Alzheimers. Dis. 24, 739–749 (2011).
  Article CAS PubMed Google Scholar
• Nunes, M. A., Viel, T. A. & Buck, H. S. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr. Alzheimer Res. 10, 104–107 (2013).
  CAS PubMed Google Scholar
• Zhang, B. et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32, 3601–3611 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Wen, Y. et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J. Biol. Chem. 286, 16504–16515 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• O'Leary, J. C. et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener. 5, 45 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Spires-Jones, T. L. et al. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci. Lett. 562, 63–68 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Stack, C. et al. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum. Mol. Genet. 23, 3716–3732 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Wischik, C. M., Bentham, P., Wischik, D. J. & Seng, K. M. Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks [abstract]. Alzheimers Dement. 4 (Suppl. 1). T167 (2008).
  Article Google Scholar
• Braak, H., Rüb, U., Jansen Steur, E. N., Del Tredici, K. & de Vos, R. A. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64, 1404–1410 (2005).
  Article CAS PubMed Google Scholar
• Hurtig, H. I. et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54, 1916–1921 (2000).
  Article CAS PubMed Google Scholar
• Montine, T. J. et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682–2685 (2010).
  Article PubMed PubMed Central Google Scholar
• Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. & Kragh-Sørensen, P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387–392 (2003).
  Article PubMed Google Scholar
• Selikhova, M. et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 132, 2947–2957 (2009).
  Article CAS PubMed Google Scholar
• Weinreb, O., Amit, T., Riederer, P., Youdim, M. B. & Mandel, S. A. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Int. Rev. Neurobiol. 100, 127–149 (2011).
  Article CAS PubMed Google Scholar
• Beal, M. F. Neuroprotective effects of creatine. Amino Acids 40, 1305–1313 (2011).
  Article CAS PubMed Google Scholar
• Beal, M. F. et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71, 543–552 (2014).
  Article PubMed Google Scholar
• Visanji, N. P. et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 22, 2488–2497 (2008).
  Article CAS PubMed Google Scholar
• US National Library of Medicine.ClinicalTrials.gov[online], (2013).
• Jin, H., Kanthasamy, A., Ghosh, A. & Anantharam, V. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta 1842, 1282–1294 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Snow, B. J. et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25, 1670–1674 (2010).
  Article PubMed Google Scholar
• Marks, W. J. et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164–1172 (2010).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov[online], (2014).
• Fitton, A. & Benfield, P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 40, 31–74 (1990).
  Article CAS PubMed Google Scholar
• Chen, X. et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl Acad. Sci. USA 110, 300–305 (2013).
  Article CAS PubMed Google Scholar
• Boddaert, N. et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110, 401–408 (2007).
  Article CAS PubMed Google Scholar
• Berman, A. E. et al. N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1 −/− mouse. Ann. Neurol. 69, 509–520 (2011).
  Article CAS PubMed Google Scholar
• Pan, J. et al. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem. Int. 54, 418–425 (2009).
  Article CAS PubMed Google Scholar
• Choudhury, M. E. et al. Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity. Brain Res. 1384, 170–178 (2011).
  Article CAS PubMed Google Scholar
• Choudhury, M. E. et al. Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors. Eur. J. Pharmacol. 689, 72–80 (2012).
  Article CAS PubMed Google Scholar
• Yürekli, V. A., Gürler, S., Nazırog˘lu, M., Ug˘uz, A. C. & Koyuncuog˘lu, H. R. Zonisamide attenuates MPP(+)-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells. Cell. Mol. Neurobiol. 33, 205–212 (2013).
  Article PubMed CAS Google Scholar
• Murata, M., Hasegawa, K. & Kanazawa, I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68, 45–50 (2007).
  Article CAS PubMed Google Scholar
• Ulusoy, G. K. et al. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. Brain Res. Bull. 85, 380–384 (2011).
  Article CAS PubMed Google Scholar
• Haddadi, R., Mohajjel Nayebi, A. & Brooshghalan, S. E. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats. Neurosci. Lett. 555, 106–111 (2013).
  Article CAS PubMed Google Scholar
• Foltynie, T. & Aviles-Olmos, I. Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic. Alzheimers Dement. 10 (Suppl. 1), S38–S46 (2014).
  Article PubMed Google Scholar
• Schneider, A. et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J. Clin. Invest. 115, 2083–2098 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Watson, F. L. et al. Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat. Neurosci. 4, 981–988 (2001).
  Article CAS PubMed Google Scholar
• Jung, K.-H. et al. Granulocyte colony-stimulating factor stimulates neurogenesis via vascular endothelial growth factor with STAT activation. Brain Res. 1073–1074, 190–201 (2006).
  Article PubMed CAS Google Scholar
• Hartung, T. Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr. Opin. Hematol. 5, 221–225 (1998).
  Article CAS PubMed Google Scholar
• Meuer, K. et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J. Neurochem. 97, 675–686 (2006).
  Article CAS PubMed Google Scholar
• Lee, S.-T. et al. Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease. Brain Res. 1194, 130–137 (2008).
  Article CAS PubMed Google Scholar
• Xue, Y.-Q., Zhao, L.-R., Guo, W.-P. & Duan, W.-M. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 146, 1245–1258 (2007).
  Article CAS PubMed Google Scholar
• Pedroso, I. et al. Use of Cuban recombinant human erythropoietin in Parkinson's disease treatment. MEDICC Rev. 14, 11–17 (2012).
  PubMed Google Scholar
• Jang, W. et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. J. Neurol. Sci. 337, 47–54 (2014).
  Article CAS PubMed Google Scholar